A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Basic science
Enrollment
12estimated
Sites
4
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-07-30 | actual | When the study began enrolling |
| Primary completion | 2026-03-21 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-21 | estimated | The whole study's end, after follow-up |
| First posted | 2018-06-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-08-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hematologic Malignancies
Interventions
- Drug: Venetoclax — also filed as ABT-199, GDC-0199, Venclexta
- Drug: ethinyl estradiol/levonorgestrel — also filed as Levora
Primary outcomes
what the primary-completion date above is the date OFTmax of Venetoclax
measured Up to approximately 59 days after initial study drug dose
Tmax of (ethinyl estradiol) EE/Levonorgestrel
measured Up to approximately 59 days after initial study drug dose
Cmax of Venetoclax
measured Up to approximately 59 days after initial study drug dose
Cmax of EE/Levonorgestrel
measured Up to approximately 59 days after initial study drug dose
t1/2 of Venetoclax
measured Up to approximately 59 days after initial study drug dose
t1/2 of EE/Levonorgestrel
measured Up to approximately 59 days after initial study drug dose
AUCt of Venetoclax
measured Up to approximately 59 days after initial study drug dose
AUCt of EE/Levonorgestrel
measured Up to approximately 59 days after initial study drug dose
AUCinf of EE/Levonorgestrel
measured Up to approximately 59 days after initial study drug dose
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed